Clinical trial
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
NCT04702737
Study timeline
Study start (actual)2021-06-10Date precision: day
Registry last updated2025-09-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Neuroendocrine Prostate Cancerunresolved
Interventions
TarlatamabDRUG · verified · RxNorm: tarlatamab
Sponsors & collaborators
Amgenlead sponsor
Mapped research locations
New YorkNew York, United States1HoustonTexas, United States1ChicagoIllinois, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1San FranciscoCalifornia, United States1ColumbusOhio, United States1IndianapolisIndiana, United States1PhoenixArizona, United States1Winston-SalemNorth Carolina, United States1MelbourneVictoria, Australia1GhentBelgium1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04702737 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.